Abnormal Pulmonary Lymphatic Flow in Patients With Lymphatic Anomalies and Respiratory Compromise

Maxim Itkin*, Deborah A. Rabinowitz, Gregory Nadolski, Patrick Stafler, Leo Mascarenhas, Denise Adams

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Background: Pulmonary involvement in lymphatic anomalies (LA) is associated with significant morbidity and mortality. Dynamic contrast-enhanced magnetic resonance lymphangiography (DCMRL) is capable of imaging the lymphatic system in a variety of pulmonary lymphatic disorders. Research Question: The objective of this study is to describe the central lymphatic anatomy in patients with LA and pulmonary involvement on DCMRL. Study Design and Methods: This prospective observational study enrolled 16 patients with LA (mean age, 17 years; range, 6-63 years; ratio of female to male patients, 9:7) with pulmonary involvement. All patients underwent DCMRL. The lymphatic system was assessed for the presence of mediastinal masses, interstitial lung disease, size and tortuosity of the thoracic duct (TD), and presence of abnormal pulmonary lymphatic flow. Results: T2-weighted imaging showed the following: mediastinal soft tissue masses in 10 patients, diffuse pulmonary interstitial thickening in 13 patients, and bone involvement in 15 patients. DCMRL revealed abnormal pulmonary lymphatic flow in 14 of 16 patients. Abnormal pulmonary lymphatic flow originated from the TD in three of 14 patients, the retroperitoneum in six of 14 patients, and both the TD and retroperitoneum in four of 14 patients. In nine of 16 patients, the TD was dilated and tortuous. In two patients the TD was not identified, and in five patients it was normal. Interpretation: Abnormal pulmonary lymphatic flow/perfusion from the TD or retroperitoneum into the lung parenchyma occurred in the majority of patients in this study. These findings can explain the interstitial lung disease and chylothorax resulting in deterioration of respiratory function in these patients. Future studies will determine whether mechanical cessation of this abnormal flow can improve pulmonary function and prolong survival in patients with LA. Clinical Trial Registration: Clinicaltrials.gov; No.: NCT02744027; URL: www.clinicaltrials.gov;

Original languageEnglish
Pages (from-to)681-691
Number of pages11
JournalChest
Volume158
Issue number2
DOIs
StatePublished - Aug 2020
Externally publishedYes

Funding

FundersFunder number
Lymphangiomatosis & Gorham Disease Alliance
Penn Orphan Disease Center
Tiffany Ferry

    Keywords

    • chylothorax
    • interstitial lung disease
    • lymphatic anomalies
    • magnetic resonance lymphangiography

    Fingerprint

    Dive into the research topics of 'Abnormal Pulmonary Lymphatic Flow in Patients With Lymphatic Anomalies and Respiratory Compromise'. Together they form a unique fingerprint.

    Cite this